You just read:

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)

News provided by

Ipsen Biopharmaceuticals Canada Inc.

Oct 16, 2018, 08:00 ET